Kangstem Biotech강스템바이오텍
217730 · KOSDAQ · ₩217730 · 강스템바이오텍
₩1,863▼ ₩2 (0.11%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 13.6% | 23.7% | 55.8% | 42.0% | 42.0% | 46.7% |
| Operating margin | −630.0% | −494.6% | −191.6% | −339.3% | −355.3% | −578.9% |
| Net margin | −381.3% | −293.4% | −103.2% | −321.6% | −334.2% | −544.0% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −15.1% | −53.9% | +31.0% | 0.0% | +57.4% | — |
| Operating income growth | −8.2% | −19.0% | +26.0% | +4.5% | +3.4% | — |
| Net income growth | −10.4% | −31.2% | +58.0% | +3.8% | +3.3% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −18.5% | −18.7% | −16.6% | −36.3% | −32.5% | −29.1% |
| Return on assets | −15.4% | −15.2% | −12.5% | −27.1% | −24.9% | −22.7% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 21.0% | 18.0% | 29.7% | 34.2% | 33.9% | 28.6% |
| Net debt to equity | −35.1% | −44.6% | −26.8% | −58.9% | 3.4% | −1.3% |
| Current ratio | 395.9% | 525.4% | 368.9% | 571.3% | 863.4% | 915.3% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Kangstem Biotech / 강스템바이오텍 / 217730 / KRX:217730
Source: KRX statistical information